ERIS1,358.00

Eris Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersMANKINDAJANTPHARMTORNTPHARMEMCUREGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹18,808 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)388.04442.26488.10488.10
Receivable Days (DSO)76.6757.8579.3579.35
Payable Days (DPO)550.86438.98368.35342.97
Cash Conversion Cycle (days)-86.1561.13199.10224.48
Working Capital Turnover-8.74-24.34-5.82-6.01
Asset Turnover0.290.410.420.42
Cash Conversion (CFO/Net Income)1.222.840.830.83
CFO/EBITDA0.721.050.480.48
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.